A comprehensive retrospective cohort study of the journey of B-cell lymphoma in Taiwan

Abstract Complete disease journey and risk factors for poor outcomes are needed to facilitate effectiveness evaluations of new therapies and clinical decision-making in B-cell Non-Hodgkin lymphoma (B-NHL), particularly in Asia where such data are lacking. This retrospective cohort study used electro...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Sung-Nan Pei, Ming-Chung Wang, Ming-Chun Ma, Ching-Yuan Kuo, Chun-Kai Liao, Hong Qiu, Lee Anne Rothwell, Yanfang Liu
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/b726675caf1f4b8b89a54c49ac26c15e
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:b726675caf1f4b8b89a54c49ac26c15e
record_format	dspace
spelling	oai:doaj.org-article:b726675caf1f4b8b89a54c49ac26c15e2021-12-02T15:55:13ZA comprehensive retrospective cohort study of the journey of B-cell lymphoma in Taiwan10.1038/s41598-021-89316-y2045-2322https://doaj.org/article/b726675caf1f4b8b89a54c49ac26c15e2021-05-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-89316-yhttps://doaj.org/toc/2045-2322Abstract Complete disease journey and risk factors for poor outcomes are needed to facilitate effectiveness evaluations of new therapies and clinical decision-making in B-cell Non-Hodgkin lymphoma (B-NHL), particularly in Asia where such data are lacking. This retrospective cohort study used electronic medical records from a regional medical centre in southern Taiwan to follow-up 441 patients newly diagnosed with common B-NHL subtypes: Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma (FL), Chronic Lymphocytic Leukaemia/Small Lymphocytic Lymphoma (CLL/SLL), Marginal Zone Lymphoma (MZL), Mantle Cell Lymphoma (MCL), and Waldenström macroglobulinemia (WM), between 01-Jan-2008 and 31-Dec-2013, until 31-Dec-2017. Treatment pathways were modelled using a Markov approach. Stage III/IV disease at diagnosis was frequent for patients with DLBCL, FL, MCL and WM. Hepatitis B surface antigen/hepatitis C virus seropositivity was 18.6%/12.3%. Clinical responses to 1st-line treatment were observed in 76.0% (DLBCL), 87.3% (FL), 86.0% (MZL), 60.0% (MCL), and 42.9% (WM) of patients. For DLBCL, disease control was achieved by ~ 50% after 1st-line, ~ 24% after 2nd-line, ~ 17% after 3rd-line. Patients with Stage III/IV DLBCL or age > 65 years at diagnosis had lower rates of active treatment, poorer disease control and higher mortality than patients with early stage disease or age ≤ 65 years. Disease flare < 6 months after 1st-line treatment was significantly associated with mortality. Despite good clinical response rates for some sub-types, survival remains poor. New treatments are needed to improve the outcome of B-NHL.Sung-Nan PeiMing-Chung WangMing-Chun MaChing-Yuan KuoChun-Kai LiaoHong QiuLee Anne RothwellYanfang LiuNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-12 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Sung-Nan Pei Ming-Chung Wang Ming-Chun Ma Ching-Yuan Kuo Chun-Kai Liao Hong Qiu Lee Anne Rothwell Yanfang Liu A comprehensive retrospective cohort study of the journey of B-cell lymphoma in Taiwan
description	Abstract Complete disease journey and risk factors for poor outcomes are needed to facilitate effectiveness evaluations of new therapies and clinical decision-making in B-cell Non-Hodgkin lymphoma (B-NHL), particularly in Asia where such data are lacking. This retrospective cohort study used electronic medical records from a regional medical centre in southern Taiwan to follow-up 441 patients newly diagnosed with common B-NHL subtypes: Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma (FL), Chronic Lymphocytic Leukaemia/Small Lymphocytic Lymphoma (CLL/SLL), Marginal Zone Lymphoma (MZL), Mantle Cell Lymphoma (MCL), and Waldenström macroglobulinemia (WM), between 01-Jan-2008 and 31-Dec-2013, until 31-Dec-2017. Treatment pathways were modelled using a Markov approach. Stage III/IV disease at diagnosis was frequent for patients with DLBCL, FL, MCL and WM. Hepatitis B surface antigen/hepatitis C virus seropositivity was 18.6%/12.3%. Clinical responses to 1st-line treatment were observed in 76.0% (DLBCL), 87.3% (FL), 86.0% (MZL), 60.0% (MCL), and 42.9% (WM) of patients. For DLBCL, disease control was achieved by ~ 50% after 1st-line, ~ 24% after 2nd-line, ~ 17% after 3rd-line. Patients with Stage III/IV DLBCL or age > 65 years at diagnosis had lower rates of active treatment, poorer disease control and higher mortality than patients with early stage disease or age ≤ 65 years. Disease flare < 6 months after 1st-line treatment was significantly associated with mortality. Despite good clinical response rates for some sub-types, survival remains poor. New treatments are needed to improve the outcome of B-NHL.
format	article
author	Sung-Nan Pei Ming-Chung Wang Ming-Chun Ma Ching-Yuan Kuo Chun-Kai Liao Hong Qiu Lee Anne Rothwell Yanfang Liu
author_facet	Sung-Nan Pei Ming-Chung Wang Ming-Chun Ma Ching-Yuan Kuo Chun-Kai Liao Hong Qiu Lee Anne Rothwell Yanfang Liu
author_sort	Sung-Nan Pei
title	A comprehensive retrospective cohort study of the journey of B-cell lymphoma in Taiwan
title_short	A comprehensive retrospective cohort study of the journey of B-cell lymphoma in Taiwan
title_full	A comprehensive retrospective cohort study of the journey of B-cell lymphoma in Taiwan
title_fullStr	A comprehensive retrospective cohort study of the journey of B-cell lymphoma in Taiwan
title_full_unstemmed	A comprehensive retrospective cohort study of the journey of B-cell lymphoma in Taiwan
title_sort	comprehensive retrospective cohort study of the journey of b-cell lymphoma in taiwan
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/b726675caf1f4b8b89a54c49ac26c15e
work_keys_str_mv	AT sungnanpei acomprehensiveretrospectivecohortstudyofthejourneyofbcelllymphomaintaiwan AT mingchungwang acomprehensiveretrospectivecohortstudyofthejourneyofbcelllymphomaintaiwan AT mingchunma acomprehensiveretrospectivecohortstudyofthejourneyofbcelllymphomaintaiwan AT chingyuankuo acomprehensiveretrospectivecohortstudyofthejourneyofbcelllymphomaintaiwan AT chunkailiao acomprehensiveretrospectivecohortstudyofthejourneyofbcelllymphomaintaiwan AT hongqiu acomprehensiveretrospectivecohortstudyofthejourneyofbcelllymphomaintaiwan AT leeannerothwell acomprehensiveretrospectivecohortstudyofthejourneyofbcelllymphomaintaiwan AT yanfangliu acomprehensiveretrospectivecohortstudyofthejourneyofbcelllymphomaintaiwan AT sungnanpei comprehensiveretrospectivecohortstudyofthejourneyofbcelllymphomaintaiwan AT mingchungwang comprehensiveretrospectivecohortstudyofthejourneyofbcelllymphomaintaiwan AT mingchunma comprehensiveretrospectivecohortstudyofthejourneyofbcelllymphomaintaiwan AT chingyuankuo comprehensiveretrospectivecohortstudyofthejourneyofbcelllymphomaintaiwan AT chunkailiao comprehensiveretrospectivecohortstudyofthejourneyofbcelllymphomaintaiwan AT hongqiu comprehensiveretrospectivecohortstudyofthejourneyofbcelllymphomaintaiwan AT leeannerothwell comprehensiveretrospectivecohortstudyofthejourneyofbcelllymphomaintaiwan AT yanfangliu comprehensiveretrospectivecohortstudyofthejourneyofbcelllymphomaintaiwan
_version_	1718385414872498176

A comprehensive retrospective cohort study of the journey of B-cell lymphoma in Taiwan

Ejemplares similares